ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed December 06 4:00PM
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
42.20
Bid
41.80
Ask
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus annonce sa participation aux prochaines journées Investisseurs

Merus annonce sa participation aux prochaines journées Investisseurs UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 07 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
lasombra lasombra 1 minute ago
Thank you for the technicals !
RDAR
aBeezlee aBeezlee 1 minute ago
None. But I scalped, couldn't help it! Random pump.
KRKNF
bradford86 bradford86 1 minute ago
warrants for sure will
FNMA
Researchfyi Researchfyi 2 minutes ago
Spot on.
LQMT
linkvest linkvest 2 minutes ago
Thought our run was going to be after the Holidays but I thinking it just might run like hell with a a couple weeks now.
ASII
lager lager 3 minutes ago
Potentially, but I have a great deal of faith in the company and the moves they are making. These dropping the price on no volume antics are just games. MGON is gonna do just fine.
MGON
TheDane TheDane 3 minutes ago
I love this guy! Fantastic interview.
PLTR
Lime Time Lime Time 4 minutes ago
Well I did buy a few at .0019 this year and hope to make a buck or two when this hits .05 again. OTC volumes picking up, that's all I'm seeing so far. If GS gets his assets ready here, it'll fly in 2025. Stay tuned for more buying volume incoming 🚀
GVSI
100lbStriper 100lbStriper 4 minutes ago
Netlist, Inc. v. Samsung Electronics Co, LTD (2:22-cv-00293)
District Court, E.D. Texas
https://www.courtlistener.com/docket/64861664/netlist-inc-v-samsung-electronics-co-ltd/?order_by=desc

861

Dec 6, 2024

Main Doc­ument

Respo
NLST
Jetmek_03052 Jetmek_03052 4 minutes ago
Honestly, I think that these small up and down movements in share price are fairly irrelevant. We’re not talking about giant moves here.

People are waiting to see solid evidence that Blackwell is indeed being produced in numbers and are somewhat anxious to see the revenue numbers t
NVDA
PlaceboJeffect PlaceboJeffect 4 minutes ago
They aren't raising A/S to *fund* any acquisition, they are raising the a/s for preferred and common share collateral, man.

Why am I debating with someone who bought 2.5mil shares just today without reading any filing and then immediately was depressed about buying it. 😆 lik
PWDY
Phantom Lord Phantom Lord 4 minutes ago
This doesn't mean anything other than that they are in dire need of cash and need a method to obtain that cash. This is path of least resistance.

They could still get a partner but they have not released enough convincing data to attract a decent partner yet.

The number
MRKR
delerious1 delerious1 5 minutes ago
Based on what?
HBARUSD
SPM555 SPM555 6 minutes ago
I don't think it was a mistake at all, I think these prices are going to pay off big time. The share structure is around 1.9 billion O/S currently but look for them to add to that down the road as they raise capital for growth and acquisitions.
PWDY
Doc logic Doc logic 6 minutes ago
dmb2,

Excellent post and worth a read and thumbs up from all longs. Thanks for sharing your insights which are much appreciated. Best wishes.
NWBO
cojoboy cojoboy 7 minutes ago
AGREED..better than me..lol..
IGPK
Mikealla Mikealla 7 minutes ago
Clown.
SMX
NomadMeteor6 NomadMeteor6 7 minutes ago
Why doesn't anyone post that's the back of Norway with 88 million shares of plug would not under any condition let plug go bankrupt and I am sure if needed to be with backup plug and have a good reason to to protect their shares in the future as they make 88 million dollars every time that goes up o
PLUG
crowin crowin 8 minutes ago
Muffler Bearing business went bankrupt, while we make money
RDAR
fuagf fuagf 9 minutes ago
Trump still has confidence in Hegseth, yet critics say he's a ‘danger to national security’

"...The 12 Worst People in Trump’s Orbit"

Related: Tulsi Gabbard's views on Russia shaped in part by Kremlin propaganda outlet, ex-aides say
U.S. intelligence has deemed t
Mikealla Mikealla 9 minutes ago
Relax pumper, HMBL moved up much more earlier this week. Can't wait for this to dump all over you.
HMBL
jimjet218 jimjet218 9 minutes ago
When (not IF) LWLG gets bought out little 'ole SilOriX is going to have a sh*t storm on their hands when someone with deep pockets goes after them.

Let that sink in.


You worry too much.

Jorge
LWLG
boston127 boston127 9 minutes ago
That is a possibilty. It went up 32%

on short volume today.
IGPK
delerious1 delerious1 9 minutes ago
BTC is a dinosaur...no utility and too much an energy pig
DOGEUSD

Your Recent History

Delayed Upgrade Clock